|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Paraneoplastic, Autoantibody Evaluation, Serum
Test CodePAVALM
Alias/See Also
AGNA; Amphiphysin Antibody, Serum; ANNA (Antineuronal Nuclear Antibody); Anti-CV2; Anti-Enteric Neuronal Antibody; Anti-GAD65 (Anti-Glutamic Acid Decarboxylase); Anti-Glial Nuclear Antibody; Anti-Hu; Anti-Purkinje Cell Cytoplasmic Antibodies; Anti-Ri; Anti-Yo; Antineuronal
APCA (Anti-Purkinje Cell Antibodies); Calcium Channel Blockers; Cerebellar Antibodies; Chorea; Cramp-fasciculation; CRMP-5, IgG; Dorsal Root Ganglion Antibody; Glutamate Decarboxylase Antibodies (GAD65); Hu Antibody; Motor End-Plate Antibody; Motor Nerve Terminal Antibodies; Myoid Antibody; N-Type Calcium Channel Antibody; Neuromyotonia; Neuronal Nuclear Antibody; Neuronal Nuclear Antibody Panel; Neuronal Potassium Channel Ab; Neuronal-Anti; Ovarian Cancer-Related Antibodies; P/Q Type Calcium Channel Antibody; Paraneoplastic Antibodies; Paraneoplastic Autoantibody Evaluation; Paraneoplastic Neurological Autoimmunity; PCA-1 (Purkinje Cell Cytoplasmic Antibodies); PCA-2 (Purkinje Cell Cytoplasmic Antibodies); PCA-Tr (Purkinje Cell Cytoplasmic Antibodies); PCAb (Purkinje Cell Cytoplasmic Antibodies); Potassium Channel Antibodies (specify); Purkinje Cell Cytoplasmic Antibodies, Type 1; Purkinje Cell Cytoplasmic Antibodies, Type 2; Purkinje Cell Cytoplasmic Antibodies, Type Tr; Ri, Anti; Stiff-man Syndrome; VGCC (Voltage-Gated Calcium Channel) Antibodies; VGKC; VGPC; Voltage-Gated Potassium Channel Ab; Yo-Anti; Neuronal Ganglionic Acetylcholine Receptor Antibody; Cantoxin Receptor Antibodies; Collapsin Response-Mediator Protein-5 Antibody (CRMP-5); Isaacs Disease; Neuromuscular Hyperexcitability; Purkinje Cell Cytoplasmic Antibodies; Alpha-3
APCA (Anti-Purkinje Cell Antibodies); Calcium Channel Blockers; Cerebellar Antibodies; Chorea; Cramp-fasciculation; CRMP-5, IgG; Dorsal Root Ganglion Antibody; Glutamate Decarboxylase Antibodies (GAD65); Hu Antibody; Motor End-Plate Antibody; Motor Nerve Terminal Antibodies; Myoid Antibody; N-Type Calcium Channel Antibody; Neuromyotonia; Neuronal Nuclear Antibody; Neuronal Nuclear Antibody Panel; Neuronal Potassium Channel Ab; Neuronal-Anti; Ovarian Cancer-Related Antibodies; P/Q Type Calcium Channel Antibody; Paraneoplastic Antibodies; Paraneoplastic Autoantibody Evaluation; Paraneoplastic Neurological Autoimmunity; PCA-1 (Purkinje Cell Cytoplasmic Antibodies); PCA-2 (Purkinje Cell Cytoplasmic Antibodies); PCA-Tr (Purkinje Cell Cytoplasmic Antibodies); PCAb (Purkinje Cell Cytoplasmic Antibodies); Potassium Channel Antibodies (specify); Purkinje Cell Cytoplasmic Antibodies, Type 1; Purkinje Cell Cytoplasmic Antibodies, Type 2; Purkinje Cell Cytoplasmic Antibodies, Type Tr; Ri, Anti; Stiff-man Syndrome; VGCC (Voltage-Gated Calcium Channel) Antibodies; VGKC; VGPC; Voltage-Gated Potassium Channel Ab; Yo-Anti; Neuronal Ganglionic Acetylcholine Receptor Antibody; Cantoxin Receptor Antibodies; Collapsin Response-Mediator Protein-5 Antibody (CRMP-5); Isaacs Disease; Neuromuscular Hyperexcitability; Purkinje Cell Cytoplasmic Antibodies; Alpha-3
Preferred Specimen
4 mL serum - red top tube
Minimum Volume
2 mL
Other Acceptable Specimens
Serum - Gold SST
Instructions
1. For optimal antibody detection, specimen collection is recommended prior to initiation of immunosuppressant medication or intravenous immunoglobulin (IVIg) treatment.
2. This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient.
3. Patient should have no general anesthetic or muscle-relaxant drugs in the previous 24 hours.
2. This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. The specific waiting period before specimen collection will depend on the isotope administered, the dose given, and the clearance rate in the individual patient.
3. Patient should have no general anesthetic or muscle-relaxant drugs in the previous 24 hours.
Transport Temperature
Refrigerated (preferred)
Specimen Stability
Room Temperature: 72 hours
Refrigerated: 28 days
Frozen: 28 days
Refrigerated: 28 days
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Grossly hemolyzed, lipemic, or icteric specimens should be rejected.
Performing Laboratory
Mayo Clinic Laboratories sendout
Additional Information
Mayo Clinic Laboratories Serum Paraneoplastic, Autoantibody Evaluation Information
Last Updated: December 3, 2021
